Moderna Breakthrough Sends MRNA Soaring: 4 mRNA Cancer Vaccine Stocks to Buy Instead

Listen to the audio version of this article (generated by AI).

Yesterday morning, Moderna made history.

The company and its partner Merck announced positive top-line results from the Phase 3 INTerpath-001 trial — the first Phase 3 readout for a personalized mRNA cancer therapy in history. The trial met both its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma.

Moderna stock recorded its largest-ever one-day gain, closing up 177% on August 19. Merck hit a record high, closing up 12.6%. BioNTech jumped 20.3%. Eli Lilly rose 4.5% pushing its market cap above $1.2 trillion — making it the first pharmaceutical company in history to cross that level. The Nasdaq Biotechnology Index climbed 4.4% to finish at its own record closing high.

I want to tell you exactly what happened. I want to tell you what it actually means. And I want to tell you the four mRNA cancer vaccine stocks that are the right way to be positioned from here—and the retail traps you should let pass.

Twenty-eight years on a trading desk. You learn to read the tape on days like this. The move is real. The question is what comes next.

Follow the money.

Executive Summary: Sector Reaction & Verdict

How the Moderna Trial Validates the Personalized Cancer Vaccine Market

The drug is called intismeran autogene. Think of it as a personalized cancer vaccine, built specifically for each patient using the unique mutational “fingerprint” of their own tumor.

Here’s how it works. A surgeon removes a melanoma. Moderna’s lab analyzes the removed tumor, identifies its specific mutations — the molecular signature that makes that cancer different from every other cancer — and builds a custom mRNA vaccine designed to teach the immune system to recognize and attack those specific cancer cells. Each therapy codes for up to 34 neoantigens tailored to that specific patient’s tumor. Then it’s combined with Merck’s Keytruda — one of the most effective immunotherapy drugs ever approved — to amplify the immune response.

The Phase 3 trial enrolled 1,137 patients. Every one of them had already undergone surgery to remove their melanoma. The question the trial asked: does this combination keep the cancer from coming back, better than Keytruda alone?

The answer, confirmed yesterday in the largest trial ever run for this kind of therapy, is yes.

The five-year Phase 2b data, presented at ASCO 2026, already showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to Keytruda alone. Yesterday’s Phase 3 confirmation made those numbers official in the most rigorous clinical setting.

This readout arrived earlier than expected. RBC Capital Markets analysts wrote that it was “surprisingly positive as we were expecting a year-end readout,” adding that “the strength of the underlying data must have been compelling to trigger significance at the interim analysis, meaningfully exceeding investor expectations.”

That last sentence is the one to read carefully. The data was strong enough to stop the trial at an interim analysis — which means the effect was so clear that waiting longer wasn’t necessary. That’s the rare result.

Biotech Stocks Moving on the Moderna Phase 3 Trial Success

mRNA cancer vaccines have been discussed for more than a decade. The science has been promising. The clinical data has been building. But a Phase 3 win — the gold standard of evidence that regulators require before approving a new drug — had never happened. Until now.

This is the first Phase 3 study to demonstrate a clinically meaningful improvement over Keytruda alone as adjuvant treatment for resected melanoma. Not a Phase 1 signal. Not a Phase 2 proof of concept. A Phase 3 randomized controlled trial in more than 1,000 patients.

The implications run far beyond melanoma.

Merck and Moderna are advancing nine total Phase 2 and Phase 3 trials across multiple tumor types — non-small cell lung cancer, bladder cancer, renal cell carcinoma, and more — using the same platform. William Blair analysts wrote yesterday morning that “positive results from INTerpath-001 add positive read-through for ongoing studies of intismeran in other cancer types,” specifically flagging a potentially registrational Phase 2 study in adjuvant renal cell carcinoma with data expected by year-end.

RBC put it simply: “INTerpath-001 success validates mRNA cancer approach, unlocking potential upside across oncology.”

That sentence is the frame for everything that follows.

Finding the Best mRNA Cancer Vaccine Stocks Beyond MRNA

I covered this exact category in my recent AI Drug Discovery piece. Today’s results are the proof-of-concept moment I said was coming. Here’s how to think about each name that moved yesterday.

Moderna (MRNA) — The Core Catalyst

Market Update: Closed up 176.97% yesterday, finishing at $174.38 from its previous $62.96 base.

Let me be direct. There is no trade in MRNA now. That trade is gone. If you held it going into yesterday morning, congratulations — take your profits. The stock is going to be volatile for weeks as the market tries to find a fair value for a company that just became something fundamentally different from what it was on August 18.

Chasing a 177% gap is the sucker play. By the time news like this hits the tape, everyone who was positioned is already selling into your buy order. Don’t fill their orders. That’s a great way to make friends with the sellers and a terrible way to make money.

The real money from yesterday’s announcement will be made in the names right next to MRNA — the ones that got validated by yesterday’s result but haven’t moved nearly as much. That’s where we focus.

Merck (MRK) — The Cleanest Strategic Play

Market Update: Vaulted 12.6% on the trial results to secure a record-high close of $152.20.

Merck is the cleaner holding of the two, in my view. Keytruda is already approved for melanoma. The combination with intismeran adds a new front-line adjuvant indication that could extend Keytruda’s commercial runway beyond its 2028 patent cliff. Merck’s fundamental business was already strong. Yesterday’s result makes it stronger.

The calculus is straightforward. Merck has a drug that already works in melanoma. The data shows combining it with Moderna’s vaccine works better. Regulators will likely want to approve something that reduces recurrence and metastasis by nearly 50% and 60%, respectively. That’s a new revenue line on top of an already-dominant drug.

The Key Risk: Keytruda faces biosimilar competition after 2028. Even with intismeran extending the franchise, the competitive landscape will change. But at $152.20, Merck is trading at a reasonable multiple on a business that just got a significant pipeline catalyst.

BioNTech (BNTX) — The Pure-Play mRNA Competitor

Market Update: Gained 20.3% to close at $111.55 on immense category volume.

This was the most interesting question on the board yesterday and I want to be honest about it.

BioNTech is the other mRNA company. It has 14 pivotal-stage oncology trials in progress, a €16.6 billion ($19.4 billion) cash pile, and has been building its cancer vaccine pipeline since the COVID era ended. The logic for the move is clear: Moderna just proved the mRNA cancer vaccine platform works. BioNTech is pursuing the same platform. The category got validated.

The Key Risk: Leerink Partners said yesterday morning that BioNTech’s rally is “likely to fade,” specifically noting that Moderna’s win validates mRNA cancer therapy broadly but doesn’t directly validate BioNTech’s specific programs, which use different targets and different patient populations. Leerink is right that you cannot automatically transfer Moderna’s result to BioNTech’s pipeline.

The Trading Verdict: That said, BioNTech at $111 is still well below its mean analyst price target of $121, and the category re-rating is real. The tape is telling you something. Monitor the insider activity. Watch the upcoming clinical readouts. If you’re going to hold BioNTech on this thesis, know exactly which trial is the next catalyst and when it reports.

Long-Term Trends in Personalized Oncology Investing

The elements getting less coverage but worth watching closely.

Eli Lilly (LLY) — The Precision Medicine Giant

Market Update: Gained 4.5% yesterday, crossing a $1.2 trillion market cap for the first time in pharmaceutical history.

Lilly is not an mRNA company. They’re an AI-era biotech built on GLP-1 weight loss drugs and a rapidly expanding cancer pipeline. Yesterday’s move reflects two things: the category tailwind lifting all quality biopharma, and the specific signal that AI-aided and precision medicine drug development works.

Lilly signed a $2.75 billion deal with Insilico Medicine in March 2026 and a $1.75 billion deal with Isomorphic Labs. They’re betting big on the same thesis — personalized, AI-designed, biology-first drugs — that Moderna just proved in a Phase 3 trial.

The Trading Verdict: At $1.2 trillion, Lilly is expensive. But they’re building the most comprehensive pipeline of any pharmaceutical company in the world right now. Yesterday’s move has legs beyond a one-day sympathy pop.

Novavax (NVAX) — The Retail Momentum Trap to Avoid

Market Update: Closed up 10.84% yesterday. And this one I want to flag specifically.

Novavax makes protein-subunit vaccines, not mRNA. There is no scientific connection between yesterday’s Moderna-Merck result and Novavax’s pipeline. This name was up because it had the word “vaccine” in its story and retail is throwing money at anything that rhymes with yesterday’s news. That’s a Twitter play, not a trade.

The Trading Verdict: If anything, if this continues to run and hits the top of its expected move, it becomes a potential short. The move is wrong. Don’t chase it.

The XBI (SPDR S&P Biotech ETF) — The Broad Category Vehicle

Market Update: Soared 5.9% on August 19 on massive volume, closing at an all-time record high of $169.55.

The XBI is the cleanest way to be in the sector broadly without picking individual names. The Nasdaq Biotechnology Index hit a record high yesterday, up 4.4%. XBI, which is equally weighted across biotech names rather than market-cap weighted, gives you direct exposure to the broad biotech re-rating that yesterday’s result is triggering.

The Trading Verdict: If you believe yesterday marks the beginning of the mRNA cancer therapy era — and I think the data says it does — XBI is how you own the entire category while the market figures out which specific names will be the biggest winners.

Illumina (ILMN) — The Core Supply-Chain Play

Market Update: Climbed 8.87% on August 19, sealing a strong closing price of $205 on massive trading volume.

Illumina is the picks-and-shovels name in this story that almost nobody is talking about. They make the genomic sequencing instruments and technology that sits at the very foundation of what Moderna’s platform requires.

Before a personalized cancer vaccine can be built for any patient, the unique mutational signature of that patient’s tumor has to be sequenced. That sequencing runs on Illumina. Every single intismeran treatment, for every single melanoma patient, starts with Illumina’s technology.

The Phase 3 result just validated a market for personalized oncology that could eventually treat hundreds of thousands of patients annually — across melanoma, lung cancer, bladder cancer, renal cell carcinoma, and more. Every one of those patients represents a sequencing event. That’s Illumina’s runway.

The Trading Verdict: ILMN finished significantly higher yesterday, but it didn’t move nearly as much as MRNA or BNTX. That’s the point. It’s the supplier behind every vaccine on this list. When the smart money finishes chasing the obvious names, this is where they look next.

Key Catalysts for the mRNA Oncology Pipeline

Three things to track from here.

1. The Data Presentation at a Medical Meeting: Merck and Moderna said they will present the full INTerpath-001 results at “an upcoming international medical meeting.” ESMO (European Society for Medical Oncology) is the most likely venue, typically held in September-October. The full data will show the exact confidence intervals, patient subgroups, and whether the effect holds across Stage IIB, IIC, III, and IV disease separately. Stronger-than-expected data at ESMO would be another catalyst. Weaker subgroup analysis would be a reason for caution.

2. The FDA Filing: The companies said they will “engage with regulators on filing submissions.” That’s the formal beginning of the approval process. A BLA (Biologics License Application) to the FDA typically takes 12 to 18 months to review under standard review timelines, or 6 months under Priority Review or Breakthrough Therapy designation — which this combination already has. Watch for the formal filing announcement. That’s the next hard date.

3. Phase 2 Renal Cell Carcinoma Readout: William Blair flagged this specifically. A potentially registrational Phase 2 trial in adjuvant renal cell carcinoma is expected to read out by year-end 2026. If that trial shows positive results, the platform expands from one cancer to two — and the entire pipeline re-rates again.

The Trading Desk Verdict: How to Position in mRNA Stocks Safely

This is not a one-way trade, even on a day like yesterday.

• The topline result is all we have. The full data — confidence intervals, overall survival trends, safety in the full Phase 3 population — isn’t available yet. The top-line is almost always the most favorable presentation. Wait for the full data before drawing final conclusions about the magnitude of the effect.
• Approval isn’t guaranteed. FDA reviewers will scrutinize the data in ways the press release doesn’t. The endpoints met — recurrence-free survival and distant metastasis-free survival — are clinically meaningful but not the same as overall survival. The FDA may require longer follow-up before granting approval, or may request additional analyses.
• Manufacturing at scale is an unsolved problem. Intismeran is customized for each individual patient. That’s the scientific breakthrough — and the commercial bottleneck. A vaccine that requires 34 personalized mRNA sequences, manufactured in weeks for each patient, at a price point healthcare systems can afford, at a scale that can serve 112,000 new melanoma cases per year in the U.S. alone — that manufacturing challenge has not been solved. It’s solvable. But “solvable” and “solved” are different things.
• The big move is rarely the stock that gapped. It’s the names right next to it. MRNA finished up 177% yesterday and is already trading at prices that reflect a future that isn’t guaranteed yet. The opportunity for new money now is in the names that got validated by yesterday’s result without having their entire commercial potential repriced in a single session. BioNTech, Illumina, and Merck all fit that description far better than MRNA at current levels.

The Bottom Line on the mRNA Cancer Revolution

For years, personalized cancer vaccines were aspirational. Scientists believed the technology was possible. The early-stage data was compelling. The logic was sound: if you can train the immune system to recognize the specific mutations inside a patient’s own tumor, you might be able to eliminate the cancer permanently.

Yesterday, in 1,137 patients across a randomized Phase 3 trial, that hypothesis became evidence.

Merck CEO Robert Davis said this was “a landmark moment.” Moderna’s CEO called it turning aspiration into reality. The trial’s principal investigator described it as establishing “a new treatment paradigm in the adjuvant melanoma setting.”

That’s not hype. That’s the clinical development community describing a result that took decades of basic science, billions of dollars of investment, and the mRNA platform that COVID vaccines proved at scale.

The mRNA cancer era just started. Not in a Phase 2 signal, not in a press release, not in a conference presentation. In a 1,137-patient Phase 3 trial that met its endpoints and advanced to regulatory filing.

Dario Amodei said last month: “AI is about to give biotech a renaissance. My instinct is we’re about to cure a lot of diseases.” Yesterday, the data gave that statement its first Phase 3 confirmation.

The cure is coming. The money is already moving.

Follow both.

Editor’s Note: Every generation or so, the way money moves gets a fundamental upgrade. The people who see it coming have the chance to get extraordinarily wealthy. Everyone else watches from the sidelines. Luke Lango says that moment is here again, and Elon Musk is behind the upgrade in an amazing way. He’s revealing exactly what to buy, including one free pick, in this presentation.

mRNA Cancer Vaccine Stocks: Frequently Asked Questions

What did Moderna and Merck announce yesterday?

Merck and Moderna announced that their Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival. This is the first positive Phase 3 readout for a personalized mRNA cancer therapy in history, reducing melanoma recurrence or death by roughly 49% in prior tracking.

Why was Moderna stock up so much yesterday?

Moderna surged a historic 177% in yesterday’s trading session because the clinical trial success validates the commercial viability of the entire mRNA oncology pipeline. Investors are repricing MRNA because a Phase 3 confirmation means formal FDA filing is the next step, potentially leading to market approval by 2027.

Which other mRNA cancer vaccine stocks moved on the Moderna trial?

While Moderna grabbed the headlines, the breakthrough triggered a massive rally across adjacent personalized cancer vaccine stocks. The primary companies moving on the news included direct mRNA competitor BioNTech (BNTX), development partner Merck (MRK), precision medicine giant Eli Lilly (LLY), and genomic sequencing provider Illumina (ILMN).

Is it too late to buy Moderna stock after yesterday’s historic move?

Chasing Moderna’s extreme 177% closing spike is highly risky because the near-term upside is already priced in. Instead, the smart money is shifting toward alternative mRNA cancer vaccine stocks that got validated by the trial results but haven’t experienced a parabolic surge.

What are the top mRNA cancer vaccine stocks to buy instead of Moderna?

The four best stocks to position in right now to capture the broader personalized oncology boom are:
1. Merck (MRK): The fundamentally clean holding sharing the direct upside of the melanoma treatment.
2. BioNTech (BNTX): The closest pure-play competitor with 14 oncology trials in progress.
3. Eli Lilly (LLY): The dominant biopharma leader investing heavily in AI-aided precision drugs.
4. Illumina (ILMN): The essential “picks-and-shovels” supply chain play that handles the genomic sequencing required for every custom vaccine.

Jonathan Rose is a former CBOE market maker and the founder of Masters in Trading at InvestorPlace. He hosts Masters in Trading Live every weekday at 11 AM ET. Follow him on X at @JRoseTrades. This article is for educational purposes only and is not investment advice. All market data as of August 20, 2026.